Quantcast

Latest ondansetron Stories

2014-08-14 08:30:05

First Patient Dosed in the EU Post-Authorization Safety Study MOUNTAIN VIEW, Calif., Aug. 14, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its European Medicines Agency (EMA) post-approval studies for ADASUVE(®) inhalation powder, pre-dispensed (loxapine). As part of the ADASUVE approval process with the EMA, Alexza is required to conduct five post-approval studies: -- a benzodiazepine interaction study - study completed and data...

2014-08-08 08:26:35

First ADASUVE Launch in Latin America MOUNTAIN VIEW, Calif., Aug. 8, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE(®) inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza's commercial partner for ADASUVE in the EU, Latin America and Commonwealth of Independent States countries. Ferrer introduced ADASUVE during a...

2014-07-08 23:08:08

Matters Involving Ongoing Litigation to Be Discussed DALLAS (PRWEB) July 08, 2014 Parties involved in lawsuits regarding the anti-psychotic drug Risperdal are scheduled to meet in the Philadelphia Court of Common Pleas to hold a conference to discuss moving litigation forward, the national law firm of Baron and Budd reports. The plaintiffs in the lawsuits accuse Janssen Pharmaceuticals, as well as parent company Johnson & Johnson, of allegedly failing to properly warn users of...

2014-05-28 16:26:44

-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI(®) (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly...

2014-05-07 23:14:54

Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name paliperidone, may contribute to an increased risk of leukopenia and neutropenia and gynecomastica according to the FDA. Washington, D.C. (PRWEB) May 07, 2014 Flood Law Group released a statement today announcing that it is now available to investigate potential claims on behalf of people who...

2014-04-09 08:28:17

TEL AVIV, Israel, April 9, 2014 /PRNewswire/ -- Medison Pharma has concluded an agreement with the medical device company Brainsway for exclusive marketing and distribution of the Deep TMS (Transcranial Magnetic Stimulation) system in Israel. Medison Pharma will be Brainsway's exclusive agent for a period of 10 years with a 5 year extension option for the system's treatment of the following indications approved by the Israeli Ministry of Health: Major depression, Bipolar...

2014-03-06 08:30:23

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the...

2014-03-03 08:31:55

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults MOUNTAIN VIEW, Calif., March 3, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE(®) (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute...

2014-01-29 08:29:25

- Data expand potential indications both within schizophrenia and to other neuropsychiatric disorders - SEATTLE, Jan. 29, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related